Veronica Mollica

5.2k total citations · 5 hit papers
155 papers, 3.0k citations indexed

About

Veronica Mollica is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Veronica Mollica has authored 155 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 107 papers in Pulmonary and Respiratory Medicine, 91 papers in Oncology and 54 papers in Surgery. Recurrent topics in Veronica Mollica's work include Cancer Immunotherapy and Biomarkers (66 papers), Renal cell carcinoma treatment (63 papers) and Bladder and Urothelial Cancer Treatments (35 papers). Veronica Mollica is often cited by papers focused on Cancer Immunotherapy and Biomarkers (66 papers), Renal cell carcinoma treatment (63 papers) and Bladder and Urothelial Cancer Treatments (35 papers). Veronica Mollica collaborates with scholars based in Italy, United States and Spain. Veronica Mollica's co-authors include Francesco Massari, Alessandro Rizzo, Matteo Santoni, Matteo Rosellini, Andrea Marchetti, Rodolfo Montironi, Nicola Battelli, Andrea Ardizzoni, Ilaria Maggio and Alessia Cimadamore and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Veronica Mollica

145 papers receiving 3.0k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma

2022 138 citations Matteo Rosellini, Andrea Marchetti et al. profile →
The impact of gender on The efficacy of immune checkpoint inhibitors in cancer patients: The MOUSEION-01 study

2022 123 citations Matteo Santoni, Alessandro Rizzo et al. Critical Reviews in Oncology/Hematology profile →
Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis

2023 117 citations Matteo Santoni, Alessandro Rizzo et al. profile →
The impact of ECOG performance status on efficacy of immunotherapy and immune-based combinations in cancer patients: the MOUSEION-06 study

2023 115 citations Veronica Mollica, Alessandro Rizzo et al. profile →
Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study

2023 107 citations Alessandro Rizzo, Veronica Mollica et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Veronica Mollica Italy	29	1.6k	1.5k	853	691	620	155	3.0k
Yuanyuan Zhao China	29	1.1k 0.7×	1.9k 1.3×	558 0.7×	475 0.7×	533 0.9×	162	3.0k
Alessia Cimadamore Italy	26	1.3k 0.8×	877 0.6×	841 1.0×	824 1.2×	577 0.9×	147	2.6k
Gwénaël Le Teuff France	25	1.2k 0.7×	918 0.6×	677 0.8×	343 0.5×	581 0.9×	97	2.7k
Feng‐Hua Wang China	31	861 0.5×	1.5k 1.0×	872 1.0×	637 0.9×	822 1.3×	126	2.9k
Carlo Barone Italy	31	1.4k 0.9×	2.3k 1.5×	769 0.9×	671 1.0×	495 0.8×	130	3.6k
William N. William United States	33	1.5k 0.9×	2.0k 1.4×	893 1.0×	901 1.3×	559 0.9×	109	4.0k
Ishmael Jaiyesimi United States	21	784 0.5×	1.3k 0.9×	632 0.7×	277 0.4×	537 0.9×	119	3.1k
Diego Cortinovis Italy	32	1.5k 0.9×	2.2k 1.5×	605 0.7×	344 0.5×	360 0.6×	181	3.4k
Takamitsu Inoue Japan	30	864 0.5×	747 0.5×	888 1.0×	633 0.9×	504 0.8×	230	2.9k
Hyo Song Kim South Korea	34	2.0k 1.3×	1.8k 1.2×	875 1.0×	809 1.2×	536 0.9×	182	3.7k

Countries citing papers authored by Veronica Mollica

Since Specialization

Citations

This map shows the geographic impact of Veronica Mollica's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Veronica Mollica with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Veronica Mollica more than expected).

Fields of papers citing papers by Veronica Mollica

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Veronica Mollica. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Veronica Mollica. The network helps show where Veronica Mollica may publish in the future.

Co-authorship network of co-authors of Veronica Mollica

This figure shows the co-authorship network connecting the top 25 collaborators of Veronica Mollica. A scholar is included among the top collaborators of Veronica Mollica based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Veronica Mollica. Veronica Mollica is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ricci, Costantino, Francesca Ambrosi, Marco Grillini, et al.. (2025). Analysis of HNF1β expression suggests that its downregulation is involved in the sarcomatoid transformation of yolk sac tumor. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. 487(5). 1151–1154.

Rosellini, Matteo, Veronica Mollica, Andrea Marchetti, et al.. (2025). Insights into the impact of chromosome 3p mutations in advanced renal cell carcinoma treated with immune-based combinations or targeted therapy: A single-center experience. Pathology - Research and Practice. 270. 155964–155964.

Monteiro, Fernando Sabino Marques, Andrey Soares, Veronica Mollica, et al.. (2024). Efficacy of immune checkpoint inhibitors combinations as first-line systemic treatment in patients with advanced urothelial carcinoma: A systematic review and network meta-analysis. Critical Reviews in Oncology/Hematology. 196. 104321–104321. 7 indexed citations

Ambrosi, Francesca, Francesco Massari, Veronica Mollica, et al.. (2024). Characterization of testicular embryonic-type neuroectodermal tumor and embryonic-type neuroectodermal tissue admixed with mature neuro-glial tissue using a broad immunohistochemical panel. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. 487(1). 221–226. 2 indexed citations

Vitale, Elsa, Deniz Can Güven, Raffaella Massafra, et al.. (2024). Sex differences in adverse events among cancer patients receiving immune checkpoint inhibitors: the MOUSEION-07 systematic review and meta-analysis. Scientific Reports. 14(1). 28309–28309. 8 indexed citations

Rosellini, Matteo, Elisa Tassinari, Andrea Marchetti, Veronica Mollica, & Francesco Massari. (2023). Re: Atezolizumab Plus Cabozantinib Versus Cabozantinib Monotherapy for Patients with Renal Cell Carcinoma After Progression with Previous Immune Checkpoint Inhibitor Treatment (CONTACT-03): A Multicentre, Randomised, Open-label, Phase 3 Trial. European Urology. 85(1). 97–98. 2 indexed citations

Ciccarese, Chiara, Sebastiano Buti, Michela Roberto, et al.. (2023). Evaluation of PBRM1, PD-L1, CD31, and CD4/CD8 ratio as a predictive signature of response to VEGFR-TKI–based therapy in patients with metastatic renal cell carcinoma (mRCC) with IMDC intermediate prognosis: Results from the APAChE-I Study.. Journal of Clinical Oncology. 41(6_suppl). 714–714. 2 indexed citations

Maloberti, Thais, Antonio De Leo, Elisa Gruppioni, et al.. (2023). Multi-Gene Next-Generation Sequencing Panel for Analysis of BRCA1/BRCA2 and Homologous Recombination Repair Genes Alterations Metastatic Castration-Resistant Prostate Cancer. International Journal of Molecular Sciences. 24(10). 8940–8940. 3 indexed citations

Gelsomino, Francesco, Rita Rinaldi, Lorenzo Muccioli, et al.. (2023). Peripheral nervous system adverse events associated with immune checkpoint inhibitors. Journal of Neurology. 270(6). 2975–2986. 28 indexed citations

10.

Ricci, Costantino, Francesca Ambrosi, Francesca Giunchi, et al.. (2023). FoxA2 is a reliable marker for the diagnosis of yolk sac tumour postpubertal‐type. Histopathology. 83(3). 465–476. 10 indexed citations

11.

Marchetti, Andrea, Matteo Rosellini, Elisa Tassinari, et al.. (2022). PARP Inhibitors and Radiometabolic Approaches in Metastatic Castration-Resistant Prostate Cancer: What’s Now, What’s New, and What’s Coming?. Cancers. 14(4). 907–907. 11 indexed citations

12.

Rizzo, Alessandro, Veronica Mollica, Andrea Marchetti, et al.. (2022). Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study. Cancers. 14(17). 4142–4142. 10 indexed citations

13.

Mollica, Veronica, Francesco Massari, Alessandro Rizzo, et al.. (2022). Genomics and Immunomics in the Treatment of Urothelial Carcinoma. Current Oncology. 29(5). 3499–3518. 9 indexed citations

14.

Mollica, Veronica, Alessandro Rizzo, Matteo Rosellini, et al.. (2021). Bone Targeting Agents in Patients with Metastatic Prostate Cancer: State of the Art. Cancers. 13(3). 546–546. 37 indexed citations

15.

Mollica, Veronica, Andrea Marchetti, Matteo Rosellini, et al.. (2021). An Insight on Novel Molecular Pathways in Metastatic Prostate Cancer: A Focus on DDR, MSI and AKT. International Journal of Molecular Sciences. 22(24). 13519–13519. 18 indexed citations

16.

Aurilio, Gaetano, Matteo Santoni, Francesco Massari, et al.. (2021). Metabolomic Profiling in Renal Cell Carcinoma Patients: News and Views. Cancers. 13(20). 5229–5229. 13 indexed citations

17.

Marchetti, Andrea, Matteo Rosellini, Veronica Mollica, et al.. (2021). The Molecular Characteristics of Non-Clear Cell Renal Cell Carcinoma: What’s the Story Morning Glory?. International Journal of Molecular Sciences. 22(12). 6237–6237. 20 indexed citations

18.

Massari, Francesco, Veronica Mollica, Alessandro Rizzo, et al.. (2020). Safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma: a systematic review and meta-analysis. Expert Opinion on Drug Safety. 19(10). 1329–1338. 67 indexed citations

19.

Rizzo, Alessandro, Veronica Mollica, Alessia Cimadamore, et al.. (2020). Is There a Role for Immunotherapy in Prostate Cancer?. Cells. 9(9). 2051–2051. 68 indexed citations

20.

Mollica, Veronica, Alessandro Rizzo, Rodolfo Montironi, et al.. (2020). Current Strategies and Novel Therapeutic Approaches for Metastatic Urothelial Carcinoma. Cancers. 12(6). 1449–1449. 71 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact